

V našem souboru nebyla celková prognóza pacienta ovlivněna nálezem IKP.

### Seznam použitých zkratk:

- IKP – incidentální karcinom prostaty
- KP – karcinom prostaty
- KM – karcinom močového měchýře
- RCP – radikální cystoprostatektomie
- WMS – Whole-Mount Section (celoplošné řezy)
- PSA – prostatický specifický antigen
- SVI – Seminal Vesical Invasion
- EPE – Extra Prostatic Extension
- PZ – periferní zóna
- TZ – přechodová zóna
- CZ – centrální zóna
- iPSA – iniciální PSA

### LITERATURA:

1. **Holund, B.** Latent prostatic cancer in a consecutive autopsy series. *Scand J Urol Nephrol* 1980; 14(1): p. 29–35.
2. **Autorino RG, Di Lorenzo R, Damiano G, et al.** Pathology of the prostate in radical cystectomy specimens: a critical review. *Surg Oncol* 2009; 18(1): 73–84.
3. **Davila HHT, Weber D, Burday S, et al.** Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function. *BJU Int* 2007; 100(5): 1026–1029.
4. **Jhavar SGC, Fisher A, Jackson SA, et al.** Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique. *Journal of clinical pathology* 2005; 58(5): 504–508.
5. **Samaratunga HR, Montironi L, True JI, et al.** International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. *Mod Pathol* 2011; 24(1): 6–15.
6. **Freedland SJME, Sutter F, Dorey, Aronson WJ.** Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. *Urology* 2003; 61(2): 365–369.
7. **Buse ST, Hofner SC, Muller E, et al.** Characterization and risk stratification of prostate cancer in patients undergoing radical cystoprostatectomy. *Int J Urol* 2013; 20(9): 866–871.
8. **Pignot GL, Salomon Y, Neuzillet A, et al.** Clinicopathological characteristics of incidental prostate cancer discovered from radical cystoprostatectomy specimen: a multicenter French study. *Ann Surg Oncol* 2014; 21(2): 684–690.
9. **Barbisan FR, Mazzucchelli M, Scarpelli A, et al.** Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer? *BJU Int* 2009; 103(8): 1058–1063.
10. **Yin MS, Bastacky U, Chandran MJ, Becich, Dhir R.** Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. *J Urol* 2008; 179(3): 892–895; discussion 895.
11. **Mazzucchelli RF, Barbisan M, Scarpelli A, et al.** Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant? *Am J Clin Pathol* 2009; 131(2): 279–283.
12. **Prošvic PP, Morávek, Šimáková E.** Incidentální adenokarcinom prostaty u pacientů po radikální cystektomii pro uroteliální karcinom. *Ces Urol* 2002; 6(1): 37–40.
13. **Kudláčková Š, Král M, Grepl M, Študent V.** Výskyt karcinomu prostaty u mužů v materiálu po RACE. *Ces Urol* 2015; 19(Suppl. B): 33–33.
14. **Zhu YP, DW Ye XD, Yao SL, et al.** Prevalence of incidental prostate cancer in patients undergoing radical cystoprostatectomy: data from China and other Asian countries. *Asian J Androl* 2009; 11(1): 104–108.
15. **Androulakakis PAHM, Schneider GH, Jacobi, Hohenfellner R.** Coincident vesical transitional cell carcinoma and prostatic carcinoma. Clinical features and treatment. *Br J Urol* 1986; 58(2): 153–156.